

Public Declaration of Interests The European Patients' Forum Ethics Committee Members

Public Declaration of Interests

١,

Name: Amanda Bok

Organisation: EHC

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in healthcare industries are those listed below:

Please indication N/A (Not applicable) as appropriate

2.1 Employment in the healthcare industry

Period	Company	Job title
None	None	None

2.2 Consultancy

• Consultancy to a company shall mean: any activity where the ethics committee member provides advice (including training on a one to one basis) to a company regardless of contractual arrangements or any form of remuneration.

Period	Company	Subject Matter	
None	None	None	

2.3. Consultancy/advisory role on patient-related activities in the last year

 The ethics committee member provides advice or participates in consultations regarding patient-related activities of a company that are strictly non-commercial (e.g. educational seminars, preparation and participation in patient meetings/trainings, development of nonproduct patient specific materials, participation in trainings of a company staff on patientcentricity etc.)

European Patients' Forum • Chaussée d'Etterbeek, 180 • 1040 Brussels • Belgium Office Phone Number: +32 (0) 2 280 23 34 • Email: info@eu-patient.eu • www.eu-patient.eu



Strategic

Period	Company	Subject Matter
2018-2019	BioMarin	Patient Education
2016	Alnylam	Patient Education

Advisory Role

Strategic advisory role for a company shall mean: any activity where the Ethics Committee members participating (with a right to vote/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction and development activities of a healthcare company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration.

Period	Company	Product	Therapeutic Indication
None	None	None	None

2.4 Financial Interests

Period	Company	Subject Matter
None	None	None

2.5 Principal Investigator

Period	Company	Subject Matter
None	None	None

2.6 Investigator

Period	Company	Subject Matter
None	None	None

2.7 Grant / Funding to Organisation /Institution in 2018 (This is the organisation which nominated you to become a member of EPF)

Company	Subject Matter and amount
Alnylam	212,500 – EHC programs



Bayer	45,000 – EHC programs
Biotest	20,000 – EHC programs
BioMarin	75,000 – EHC programs
CSL Behring	65,000 – EHC programs
Kedrion	37,000 – EHC programs
Novo Nordisk	45,000 – EHC programs
Pfizer	192,500 – EHC programs
Roche	132,500 – EHC programs
Sanofi	7,500 – EHC programs
Shire	170,000 – EHC programs
Sobi	243,000 – EHC programs
Spark	40,000 – EHC programs
UniQure	11,866 – EHC programs

https://www.ehc.eu/financial-information-2018/

2.8 Close Family Member Interest

Period	Company	Interest
None	None	None

2.9 Any Other Interests or Facts

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EPF website.

Full Name	Amanda Bok
Date	29-04-20